EN DE
Watch Da An Gene Co Ltd of Sun Yat-Sen University for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Da An Gene Co Ltd of Sun Yat-Sen University (002030) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Da An Gene Co Ltd of Sun Yat-Sen University stock ¥1.47, price ¥5.27, that is 72.1% below the price, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE000001KP1

DA Da An Gene Co Ltd of Sun Yat-Sen University logo Thin data Nov 6, 2026

Da An Gene Co Ltd of Sun Yat-Sen University

002030 · SHE
Solid, but very expensive

Our calculation puts a fair price 72% below what the stock costs today.

Low debt
Generates free cash flow
Revenue last quarter +18% vs. a year ago.
Quality 50/100
Mixed vs. peers (6/12)
Fair value ¥1.47 · Strongly overvalued (−72.1%)
Weak Growth (revenue 5y −32.3 %/yr in CNY)
Loss-making · -95.7% net margin (TTM)
Narrow moat 16/100
Thin data
Watch Da An Gene Co Ltd of Sun Yat-Sen University for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥19.52 ¥4.77 Fair Value ¥1.47 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range ¥4.77 – ¥19.52 · fair‑value band ¥1.02 – ¥2.30 · the ¥5.27 price screens above the ¥1.47 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Da An Gene Co Ltd of Sun Yat-Sen University in your weekly email

Every Wednesday you see whether Da An Gene Co Ltd of Sun Yat-Sen University is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Daan Gene Co., Ltd., together with its subsidiaries, researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables in China. It operates through two segments, Biological Products and Related Business and Financial Business.

Show moreShow less

The company offers reagents for hepatitis virus, sexually transmitted infections, blood screening, digestive pathogens, coronavirus disease (COVID-19), pharmacogenomics, viral transport medium, human papillomavirus, human immunodeficiency virus, respiratory infections, public health, tumor maker, and nucleic acid extraction, as well as polymerase chain reaction, sample preparation, and nucleic extraction systems for molecular diagnosis; COVID-19 rapid test kit and chemiluminescence immunoassay analyzers for immunoassay; liquid based cytology production and automatic sample transfer machines for pathology tests; and auto biochemistry analyzers and chemistry reagents for clinical chemistry.

It also provides medical laboratory and health consultation services, such as genetic susceptibility gene testing, tumor marker testing, cervical cancer screening, routine physical examination, and other health services.

The company sells its products under the Daan Gene, Darui Biology, LBP, and Zhongshan Bio-Tech brands.

In addition, it is involved in biological technology, biomedicine and biopharmaceutical, clinical test, business, software development, trading, hospital investment management, capital market, insurance agent, management, finance lease, microfinance, commercial factoring, loan, consulting, and technology promotion and application service industry services.

The company was formerly known as Da An Gene Co., Ltd. of Sun Yat-Sen University. Daan Gene Co., Ltd. was founded in 1988 and is headquartered in Guangzhou, China.

Stock analysis

Da An Gene Co Ltd of Sun Yat-Sen University (002030) currently trades at ¥5.27, while our model-based Fair Value estimate is ¥1.47, 72% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of ¥1.69 per share, and 0 of the 10 models we run sit above the ¥5.27 price.

Bear case: the Multiples group reads lowest at ¥0.8950, and 10 of the 10 models stay below the price. Data coverage for this calculation is low.

Scenario range: ¥1.02 (bear) to ¥2.30 (bull), the price of ¥5.27 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Da An Gene Co Ltd of Sun Yat-Sen University reported revenue of 758M CNY in FY2025 versus 7.7B CNY in FY2021, a compound −43.9%/yr. Reported net income was −744M CNY in FY2025.

Key figures

Market cap 7.4B CNY (≈ $1.1B) Small · P/S ratio 9.62 · EPS (TTM) ¥−0.5200 · Dividend yield 0.1% · Net margin −95.7% · Return on equity −10.2% · Return on assets (EBIT) 13.9% (5-year average) · Operating margin −36.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).

What moves the price

The share trades about 32% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −72%, 002030 screens richer than that median.

Fair Value models

Bear ¥1.02 Fair Value ¥1.47 Bull ¥2.30
Price ¥5.27 · Downside -72.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF ¥1.22 ¥1.64 ¥2.91 78
5Y EBITDA Exit ¥0.6400 ¥0.7000 ¥0.8100 77
Growth DCF ¥1.17 ¥1.74 ¥2.81 77
All 10 models by family
DCF Models
FCF DCF ¥1.22 ¥1.64 ¥2.91 78
5Y Revenue Exit ¥1.02 ¥1.47 ¥2.41 71
5Y EBITDA Exit ¥0.6400 ¥0.7000 ¥0.8100 77
10Y Revenue Exit ¥1.07 ¥1.84 ¥2.30 67
10Y EBITDA Exit ¥0.8300 ¥1.06 ¥1.36 70
Multiples
EV/EBITDA ¥0.5300 ¥0.5300 ¥0.5400 67
EV/Revenue ¥1.03 ¥1.26 ¥1.48 54
Asset-Based
NCAV (Graham) ¥0.6900 ¥1.05 ¥1.31 54
Growth DCF
Growth DCF ¥1.17 ¥1.74 ¥2.81 77
Rev-Margin DCF ¥1.03 ¥1.63 ¥2.77 71

Open the full fair value analysis →

Quality Score breakdown

Overall quality 50/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 42
Are margins and returns getting better?
Cashflow 51
Do the profits arrive as real cash?
Financial strength 80
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 69
How calm the share price moves, does not count
Price momentum 32
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 13
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 17/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−11.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−60.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−32.3%
Start year 2020 (pandemic). Over 10 years: −6.4% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
53.8% (2021) → −39.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+39.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +36.8% a year for the price.

002030 screens overvalued: fair value 72% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Da An Gene Co Ltd of Sun Yat-Sen University with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 50 · Above median
Fair Value upside −72.1% · Below median
Profitability
Return on assets −8.8% · Above median
Net margin (12 months) −95.7% · Bottom 25%
Operating margin (12 months) −36.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 17.9% · Above median
Dividend yield (12 months) 0.1% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.04× · Cheapest 25%
P/S (12 months) 9.53× · Pricier than median
Price / free cash flow (fiscal year) 91.9× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)90 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)2 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 002030
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 002030
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs 002030
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 002030
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 002030
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs 002030
argenx SE ARGX $927.21 $908.40 −2% vs 002030
CSL Limited CSL A$202.04 A$183.04 −9% vs 002030
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 002030
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 002030

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Da An Gene Co Ltd of Sun Yat-Sen University: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Da An Gene Co Ltd of Sun Yat-Sen University Fair Value". https://www.fairvalue-calculator.com/stock/002030

Frequently asked questions

Is Da An Gene Co Ltd of Sun Yat-Sen University (002030) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of ¥1.47 versus a price of ¥5.27, about 72% lower (overvalued).
What is the fair value of 002030?
Our model-based fair value for Da An Gene Co Ltd of Sun Yat-Sen University is ¥1.47 (as of Nov 6, 2026), built from audited fundamentals. The current price: ¥5.27.
What is the quality score of 002030?
Da An Gene Co Ltd of Sun Yat-Sen University has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Da An Gene Co Ltd of Sun Yat-Sen University (002030)?
Our model-based price target is the fair value of ¥1.47 (as of Nov 6, 2026) from 10 valuation models. Cautious scenario ¥1.02, optimistic scenario ¥2.30. It is a calculation from audited fundamentals, not an analyst target.
What is the Da An Gene Co Ltd of Sun Yat-Sen University stock forecast for 2026?
Our models put fair value at ¥1.47, about 72% lower versus a price of ¥5.27 (overvalued). Cautious scenario ¥1.02, optimistic scenario ¥2.30. The calculation is refreshed regularly with new filings.
What is the revenue of Da An Gene Co Ltd of Sun Yat-Sen University (002030)?
Da An Gene Co Ltd of Sun Yat-Sen University reported trailing-twelve-month revenue of about 776M CNY (latest available figure, as of Nov 6, 2026).
Does Da An Gene Co Ltd of Sun Yat-Sen University pay a dividend?
Da An Gene Co Ltd of Sun Yat-Sen University currently shows a dividend yield of 0.11% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Da An Gene Co Ltd of Sun Yat-Sen University (002030)?
Da An Gene Co Ltd of Sun Yat-Sen University has a dividend yield of 0.1%.
What growth is priced into Da An Gene Co Ltd of Sun Yat-Sen University (002030)?
For today's price to be fair in a discounted-cash-flow model, Da An Gene Co Ltd of Sun Yat-Sen University would have to grow free cash flow by +39.1 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -32.3 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of 002030 use?
Our models discount Da An Gene Co Ltd of Sun Yat-Sen University at 10.4 %: a base by market capitalisation (small), damped by beta 0.45, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Da An Gene Co Ltd of Sun Yat-Sen University that is +39.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Da An Gene Co Ltd of Sun Yat-Sen University (002030) delivered so far?
Over the past 5 years revenue at Da An Gene Co Ltd of Sun Yat-Sen University grew -32.3 % a year. The price currently implies free-cash-flow growth of +39.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Da An Gene Co Ltd of Sun Yat-Sen University (002030) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Da An Gene Co Ltd of Sun Yat-Sen University (+39.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Da An Gene Co Ltd of Sun Yat-Sen University (002030)?
The free-cash-flow yield on the price is 1.09 %: that much free cash flow Da An Gene Co Ltd of Sun Yat-Sen University produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Da An Gene Co Ltd of Sun Yat-Sen University (002030)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Da An Gene Co Ltd of Sun Yat-Sen University it is ¥1.47 per share (as of Nov 6, 2026), against a price of ¥5.27. It is the blended result of 10 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Da An Gene Co Ltd of Sun Yat-Sen University stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 002030 trades above its calculated fair value: price ¥5.27, fair value ¥1.47, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002030?
No. The price is what the market pays today (¥5.27); the fair value is what the company's own numbers justify (¥1.47). For Da An Gene Co Ltd of Sun Yat-Sen University the two are ¥3.80 per share apart. That gap is exactly why we show both numbers side by side.
How much is Da An Gene Co Ltd of Sun Yat-Sen University worth?
The market values Da An Gene Co Ltd of Sun Yat-Sen University at about 7.4B CNY (market capitalisation, as of Nov 6, 2026). Per share that is ¥5.27; our models calculate a fair value of ¥1.47 per share.
What do the bullish and bearish scenarios say about 002030?
Our models span a range for Da An Gene Co Ltd of Sun Yat-Sen University: cautious scenario ¥1.02, base ¥1.47, optimistic ¥2.30 per share (as of Nov 6, 2026, price ¥5.27). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Da An Gene Co Ltd of Sun Yat-Sen University (002030)?
Balance-sheet figures for Da An Gene Co Ltd of Sun Yat-Sen University (as of Nov 6, 2026): return on equity −10.2%. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 002030 from its 52-week high?
Da An Gene Co Ltd of Sun Yat-Sen University trades at ¥5.27, about 32% below its 52-week high of ¥7.71 and 8% above the low of ¥4.88 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥1.47 is for.
Which stocks are comparable to Da An Gene Co Ltd of Sun Yat-Sen University?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Da An Gene Co Ltd of Sun Yat-Sen University stock attractive at the current price?
The data as of Nov 6, 2026: price ¥5.27, calculated fair value ¥1.47 (−72%), Quality Score 50/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002030 calculated?
We run Da An Gene Co Ltd of Sun Yat-Sen University through 10 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of ¥1.47 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Da An Gene Co Ltd of Sun Yat-Sen University itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Da An Gene Co Ltd of Sun Yat-Sen University (002030)?
The closing price on Nov 6, 2026 was ¥5.27. Our model-based fair value is ¥1.47, about 72% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Da An Gene Co Ltd of Sun Yat-Sen University right now?
The price sits above even our optimistic bull case (¥2.30). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥1.02 to ¥2.30) leaves room in how you read the outcome.
Where does the earnings growth of Da An Gene Co Ltd of Sun Yat-Sen University (002030) come from?
Earnings per share at Da An Gene Co Ltd of Sun Yat-Sen University grew +43.0 % a year from 2013 to 2024. Broken into its drivers: revenue per share +23.1 %, EBIT margin +17.4 %, tax rate +0.7 %, residual (interest, one-offs) −1.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Da An Gene Co Ltd of Sun Yat-Sen University

How large is the market capitalisation of Da An Gene Co Ltd of Sun Yat-Sen University (002030)?
The market capitalisation of Da An Gene Co Ltd of Sun Yat-Sen University is 7.4B CNY (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Da An Gene Co Ltd of Sun Yat-Sen University (002030)?
The price-to-sales ratio of Da An Gene Co Ltd of Sun Yat-Sen University is 9.62 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Da An Gene Co Ltd of Sun Yat-Sen University (002030)?
Earnings per share at Da An Gene Co Ltd of Sun Yat-Sen University are ¥−0.5200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Da An Gene Co Ltd of Sun Yat-Sen University (002030)?
The dividend yield of Da An Gene Co Ltd of Sun Yat-Sen University is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Da An Gene Co Ltd of Sun Yat-Sen University (002030)?
The net margin of Da An Gene Co Ltd of Sun Yat-Sen University is −95.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Da An Gene Co Ltd of Sun Yat-Sen University (002030)?
The return on equity (ROE) of Da An Gene Co Ltd of Sun Yat-Sen University is −10.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Da An Gene Co Ltd of Sun Yat-Sen University (002030)?
On an EBIT basis the return on assets of Da An Gene Co Ltd of Sun Yat-Sen University is 13.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Da An Gene Co Ltd of Sun Yat-Sen University (002030)?
The operating margin of Da An Gene Co Ltd of Sun Yat-Sen University is −36.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Da An Gene Co Ltd of Sun Yat-Sen University (002030)?
Revenue at Da An Gene Co Ltd of Sun Yat-Sen University is growing +17.9% versus a year earlier (3y avg −60.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Da An Gene Co Ltd of Sun Yat-Sen University (002030)?
Earnings per share at Da An Gene Co Ltd of Sun Yat-Sen University are growing −80.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Da An Gene Co Ltd of Sun Yat-Sen University (002030) hold?
Da An Gene Co Ltd of Sun Yat-Sen University holds more cash than debt, 715M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Da An Gene Co Ltd of Sun Yat-Sen University in the live analysis

One click puts Da An Gene Co Ltd of Sun Yat-Sen University on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.